TIGIT and neoplasm: Tumour-bearing mice were treated with control, Fc-inert anti-PD-L1, and/or IgG2a and IgG2b anti-TIGIT antibodies, and tumour-infiltrating leukocytes were captured and sequenced using scRNA-seq (n = 35,358 (tumour T and NK cells) and n = 4,261 (tumour myeloid cells); Extended Data Fig. 6a,b).